Previously published meta-analyses comparing the efficacy and safety of rapid-acting insulin analogs with RHI have consistently shown a modest but statistically significant difference in A1c in patients with Type 1 or Type 2 diabetes, in favor of rapid-acting analogs.18–20 These meta-analyses were based on systematic reviews of published trial data. Here, INS is linked to type 2 diabetes mellitus.